Faculty profile

Michel Roberge

ResearcherBiochemistry and Molecular BiologyUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses may be missing. Find their university profile.

Michel Roberge

Researcher

Biochemistry and Molecular Biology

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
4 publications in the last five years, latest in 2022.
Principal investigator on 5 research grants (5 CIHR), most recently in 2017.
Supervised 2 trainees who won CIHR awards, most recently in 2017.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

5,089

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Antisense Oligonucleotides Epidermolysis Bullosa Gene Editing Humanized Mouse Models Readthrough Drugs Skin Targeted Therapies Aminoglycosides

Latest papers

Clionamines stimulate autophagy, inhibit Mycobacterium tuberculosis survival in macrophages, and target Pik1.
Cell chemical biology · 2022
Read-Through for Nonsense Mutations in Type XVII Collagen‒Deficient Junctional Epidermolysis Bullosa.
The Journal of investigative dermatology · 2022
NanoLuc reporters identify COL4A5 nonsense mutations susceptible to drug-induced stop codon readthrough.
iScience · 2022

All 79 publications

Latest funding

Discovery of small molecules targeting SARS-CoV-2 frameshifting using a rapid yeast platform
CIHR · 2020 · Co-investigator
$445,230
Mutation-targeted gene and pharmacological therapies for dystrophic and junctional Epidermolysis Bullosa
CIHR · 2017 · Nominated PI
$305,439
Inhibitors of PNT domain polymerization as a novel therapy to target ETV6 chimeric oncoproteins
CIHR · 2017 · Supervisor
$105,000

All 14 grants and awards

79 publications.

Clionamines stimulate autophagy, inhibit Mycobacterium tuberculosis survival in macrophages, and target Pik1.

Persaud R, Li SC, Chao JD, Forestieri R, Donohue E, Balgi AD, Zheng X, Chao JT, Yashiroda Y, Yoshimura M, Loewen CJR, Gingras AC, Boone C, Av-Gay Y, Roberge M, Andersen RJ

Cell chemical biology2022

DOI: 10.1016/j.chembiol.2021.07.017 PMID: 34520745

Read-Through for Nonsense Mutations in Type XVII Collagen‒Deficient Junctional Epidermolysis Bullosa.

Has C, Sayar SB, Zheng S, Chacón-Solano E, Condrat I, Yadav A, Roberge M, Larcher Laguzzi F

The Journal of investigative dermatology2022

DOI: 10.1016/j.jid.2021.09.018 PMID: 34673051

NanoLuc reporters identify COL4A5 nonsense mutations susceptible to drug-induced stop codon readthrough.

Omachi K, Kai H, Roberge M, Miner JH

iScience2022

DOI: 10.1016/j.isci.2022.103891 PMID: 35243249

Nonselective TRPC channel inhibition and suppression of aminoglycoside-induced premature termination codon readthrough by the small molecule AC1903.

Baradaran-Heravi A, Bauer CC, Pickles IB, Hosseini-Farahabadi S, Balgi AD, Choi K, Linley DM, Beech DJ, Roberge M, Bon RS

The Journal of biological chemistry2022

DOI: 10.1016/j.jbc.2021.101546 PMID: 34999117

Reducing the Toxicity of Designer Aminoglycosides as Nonsense Mutation Readthrough Agents for Therapeutic Targets.

Popadynec M, Baradaran-Heravi A, Alford B, Cameron SA, Clinch K, Mason JM, Rendle PM, Zubkova OV, Gan Z, Liu H, Rebollo O, Whitfield DM, Yan F, Roberge M, Powell DA

ACS medicinal chemistry letters2021

DOI: 10.1021/acsmedchemlett.1c00349 PMID: 34531957

A Multipronged Screening Approach Targeting Inhibition of ETV6 PNT Domain Polymerization.

Gerak CAN, Zhang SM, Balgi AD, Sadowski IJ, Sessions RB, McIntosh LP, Roberge M

SLAS discovery : advancing life sciences R & D2021Senior author

DOI: 10.1177/2472555220979599 PMID: 33345679

Thiopurines activate an antiviral unfolded protein response that blocks influenza A virus glycoprotein accumulation.

Slaine PD, Kleer M, Duguay BA, Pringle ES, Kadijk E, Ying S, Balgi A, Roberge M, McCormick C, Khaperskyy DA

Journal of virology2021

DOI: 10.1128/jvi.00453-21 PMID: 33762409

Small molecule Y-320 stimulates ribosome biogenesis, protein synthesis, and aminoglycoside-induced premature termination codon readthrough.

Hosseini-Farahabadi S, Baradaran-Heravi A, Zimmerman C, Choi K, Flibotte S, Roberge M

PLoS biology2021Senior author

DOI: 10.1371/journal.pbio.3001221 PMID: 33939688

Effect of small molecule eRF3 degraders on premature termination codon readthrough.

Baradaran-Heravi A, Balgi AD, Hosseini-Farahabadi S, Choi K, Has C, Roberge M

Nucleic acids research2021Senior author

DOI: 10.1093/nar/gkab194 PMID: 33764477

Biophysical characterization of the ETV6 PNT domain polymerization interfaces.

Gerak CAN, Cho SY, Kolesnikov M, Okon M, Murphy MEP, Sessions RB, Roberge M, McIntosh LP

The Journal of biological chemistry2021

DOI: 10.1016/j.jbc.2021.100284 PMID: 33450226

Discovery of small molecules targeting SARS-CoV-2 frameshifting using a rapid yeast platform

Co-investigatorCIHR2020Operating Grant: COVID-19 - Project Grant

Principal investigators: Jan, Eric

Keywords: Recoding; Rna; Translation; Virus

$445,230

Mutation-targeted gene and pharmacological therapies for dystrophic and junctional Epidermolysis Bullosa

Nominated PICIHR2017Team Grant: E-Rare Joint Transnational Call

Principal investigators: Roberge, Michel

Keywords: Antisense Oligonucleotides; Epidermolysis Bullosa; Gene Editing; Humanized Mouse Models; Readthrough Drugs; Skin; Targeted Therapies

$305,439

Inhibitors of PNT domain polymerization as a novel therapy to target ETV6 chimeric oncoproteins

SupervisorCIHR2017Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

Principal investigators: Gerak, Chloe A

Keywords: Chemical Biology; Fragment-Based Drug Design; High-Throughput Screening; Isothermal Titration Calorimetry; Nuclear Magnetic Resonance Spectroscopy; Oncoprotein; Protein-Protein Interaction; Receptor Tyrosine Kinase; Structural Biology; Transcription Factor

$105,000

Preclinical evaluation of a gentamicin analog as a treatment for genetic diseases and cancer due to a premature termination codon.

Nominated PICIHR2015Proof of Principle Program - Phase I

Principal investigators: Roberge, Michel

Keywords: Aminoglycosides; Animal Studies; Cancer; New Therapeutics; Nonsense Mutations; Premature Stop Codon Readthrough; Rare Genetic Diseases; Tp53; Tumour Xenografts

$150,059

Chromosome instability and synthetic lethality in yeast and cancer

Co-investigatorCIHR2015Foundation Grant

Principal investigators: Hieter, Philip A

Keywords: C. Elegans Genetics; Cancer Therapeutics; Chromosome Biology; Chromosome Instability Genes; Dna Repair; Genome Stability; Mechanisms Of Aneuploidy; Model Organisms And Human Disease; Synthetic Lethality; Yeast Genetics

$2,526,307

Lipid nanomedicines for health and disease

Co-investigatorCIHR2015Foundation Grant

Principal investigators: Cullis, Pieter R

Keywords: Anticancer; Drug Delivery System; Gene Therapy; Immunosuppressant; Lipid Nanoparticles; Mrna; Nanomedicine; Sirna; Small Molecule Drugs; Trigger Release

$2,121,669

Molecular mechanisms of autophagy regulation

Co-investigatorCIHR2014Foundation Grant

Principal investigators: Yip, Calvin K

Keywords: Atg Proteins; Autophagosome; Macroautophagy; Membrane Remodeling; Protein Kinase; Selective Autophagy; Signal Transduction; Structural Biology; Transcriptional Regulation; Transmission Electron Microscopy

$739,963

Preclinical Development of a novel M2 Channel Inhibitor for the Treatment and Prevention of Influenza

Nominated PICIHR2013Proof of Principle Program - Phase I

Principal investigators: Roberge, Michel

Keywords: Amantadine; Antiviral Assay; Chemical Synthesis; Drug Lead; Influenza M2; Preclinical Development; Yeast Screening Assay

$160,000

Study of new mTOR signaling inhibitors as potential treatment for tuberculosis sclerosis complex

SupervisorCIHR2010Master's Award: Canada Graduate Scholarships

Principal investigators: King, Dustin T

Keywords: Antiangina Drug; Antiarrythmia Drug; Antiparasitic Drug; Benign Tumour; Inhibitor; Mtorc1; Rapamycin; Receptor Signaling; Therapeutic Development; Tuberous Sclerosis Complex

$17,500

NSERC CREATE Graduate program in Genome Science and Technology

Co-investigatorNSERC2009Collaborative Research and Training Experience

Principal investigators: Withers, Stephen

$1,650,000

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Michel Roberge

Research

Latest papers

Latest funding

Clionamines stimulate autophagy, inhibit Mycobacterium tuberculosis survival in macrophages, and target Pik1.

Read-Through for Nonsense Mutations in Type XVII Collagen&#x2012;Deficient Junctional Epidermolysis Bullosa.

NanoLuc reporters identify COL4A5 nonsense mutations susceptible to drug-induced stop codon readthrough.

Nonselective TRPC channel inhibition and suppression of aminoglycoside-induced premature termination codon readthrough by the small molecule AC1903.

Reducing the Toxicity of Designer Aminoglycosides as Nonsense Mutation Readthrough Agents for Therapeutic Targets.

A Multipronged Screening Approach Targeting Inhibition of ETV6 PNT Domain Polymerization.

Thiopurines activate an antiviral unfolded protein response that blocks influenza A virus glycoprotein accumulation.

Small molecule Y-320 stimulates ribosome biogenesis, protein synthesis, and aminoglycoside-induced premature termination codon readthrough.

Effect of small molecule eRF3 degraders on premature termination codon readthrough.

Biophysical characterization of the ETV6 PNT domain polymerization interfaces.

NSERC CREATE Graduate program in Genome Science and Technology

Frequent collaborators

Yossef Av-Gay

Eric Jan

Craig McCormick

Corey Nislow

Masahiro Niikura

Shoukat Dedhar

Donald Moerman

Dusica Maysinger

Ivan Topisirovic

Martin Gleave

Steve Jean

Arnim Pause

John Orlowski

Amina Zoubeidi

Ivan Topisirovic

Xi-Long Zheng

Audrey Tung

Urban Emmenegger

Khosrow Adeli

Richard Sowery

Aly Karsan

Michael Sacher

Anne-Claude Gingras

Ruth Slack

Nahum Sonenberg

Charles Boone

Honglin Luo

Calvin Roskelley

York Hsiang

Thibault Mayor

Eldad Zacksenhaus

Isabella Caniggia

Xiaoyan Jiang

Andre Bedard

Franck Duong

John Lee

Read-Through for Nonsense Mutations in Type XVII Collagen‒Deficient Junctional Epidermolysis Bullosa.